Parkinson's disease is a progressive neurodegenerative disorder which often results in disability. If pharmacological agents could slow the progression of disease early disability, job loss, and nursing home placement might be delayed. This clinical trial utilizing a randomized, double blind design will evaluate the efficacy of one or more pharmacological agents for slowing progression of Parkinson's disease and will determine the toxicity and tolerability of these agents. The trial will enroll patients with Parkinson's disease who recently started dopaminergic therapy, will be able to detect small treatment effects, will incorporate innovative sample follow-up methods, and will be able to distinguish neuroprotective effects from occult symptomatic benefits. This center will be one of 42 clinical centers designated to participate in this study.
|Wills, Anne-Marie A; Pérez, Adriana; Wang, Jue et al. (2016) Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1 JAMA Neurol 73:321-8|
|Elm, Jordan J; NINDS NET-PD Investigators (2012) Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 27:1513-21|
|Mauldin, Patrick D; Guimaraes, Paulo; Albin, Roger L et al. (2008) Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy. Clin Ther 30:1553-7|